GlassScriptPhysician profile
Karen Burroughs
NPI 1265437214
$3,407.11
in general payments reported to CMS, 2019-2025
28 companies · $829 in 2025
The $829 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $32.79 · 2021: $440 · 2022: $544 · 2023: $730 · 2024: $404 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918 · Education: $44.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.86 |
| Education | $44.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.09 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $417.87 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $267.04 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.84 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $226.84 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $204.27 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $200.68 | 2025 | Gemtesa |
| Novo Nordisk INC | $196.51 | 2019-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.56 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $140.14 | 2019-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $131.32 | 2021-2024 | Arexvy |
| Dexcom, INC. | $119.27 | 2023 | Dexcom G7 Gss (161) |
| Bayer Healthcare Pharmaceuticals INC. | $79.34 | 2022-2025 | |
| Ge Healthcare | $71.92 | 2024 | |
| Abbott Laboratories | $57.46 | 2021-2024 | Proclaim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $48.24 | 2025 | Auvelity |
| Currax Pharmaceuticals LLC | $37.03 | 2022-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $34.01 | 2019-2025 | Capvaxive, Enflonsia, M-M-R II |
| Kowa Pharmaceuticals America, INC. | $23.59 | 2022 | |
| Lundbeck LLC | $23.47 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $23.45 | 2019 | |
| Allergan, INC. | $22.52 | 2019 | |
| Ibsa Pharma INC. | $20.10 | 2023 | Tirosint, Licart |
| Exact Sciences Corporation | $16.17 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.24 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $13.97 | 2019 | |
| Biogen, INC. | $12.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Burroughs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.